Acquisitions and IPOs across health and longevity.
Explore what each startup built, who acquired it, the value disclosed, and how long it took to reach an exit.
76 exits
Developed long-acting antibody medicines designed to relieve chronic itch and inflammatory skin disease.
Developed cancer medicines that used antibodies to carry protein-degrading drugs directly into tumor cells.
Developed an oral medicine designed to work alongside standard treatment for a rare bone-marrow cancer.
Developed an antibody treatment for a virus that attacks the kidney in transplant patients.
Developed small-molecule medicines designed to calm the immune system in inflammatory conditions.
Offered clinical genetic tests that identified inherited disease risks and guided personalized care decisions.
Developed injectable medicines targeting metabolic diseases, including obesity and diabetes.
Developed a non-steroidal topical medicine for treating plaque psoriasis and atopic dermatitis.
Developed fish-skin grafts that help the body repair chronic, diabetic, burn, surgical, and trauma wounds.
Developed collagen implants that supported tendon and ligament healing after orthopedic and sports injuries.
Offered virtual weight-management care combining clinician visits, medication access, and ongoing coaching.
Developed gene therapies for retinal diseases by targeting biological pathways involved in vision loss.
Developed blood and tissue genomic tests that profiled cancers and helped guide targeted treatments.
Developed antiviral medicines for respiratory syncytial virus in infants and other vulnerable patients.
Developed real-time ultrasound systems that helped surgeons visualize anatomy and guide decisions during operations.